ANAB
AnaptysBio, Inc.NASDAQHealthcare$57.68+1.67%ClosedMarket Cap: $1.66B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
46.62
P/S
7.65
EV/EBITDA
27.68
DCF Value
$-350.12
FCF Yield
1.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.0%
Operating Margin
20.4%
Net Margin
-5.6%
ROE
1813.8%
ROA
-3.6%
ROIC
14.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $108.2M | 199.8% | $66.9M | $49.6M | $1.58 | — |
| FY 2025 | $234.6M | 99.0% | $47.9M | $-13.2M | $-0.46 | — |
| Q3 2025 | $76.3M | 58.8% | $34.7M | $15.1M | $0.52 | — |
| Q2 2025 | $22.3M | -69.9% | $-26.2M | $-38.6M | $-1.34 | — |
| Q1 2025 | $27.8M | -48.3% | $-27.5M | $-39.3M | $-1.28 | — |
| Q4 2024 | $43.1M | 1.2% | $-9.7M | $-21.8M | $-0.77 | — |
| FY 2024 | $91.3M | -79.5% | $-114.9M | $-145.2M | $-5.12 | — |
| Q3 2024 | $30.0M | -40.6% | $-22.8M | $-32.9M | $-1.14 | — |
| Q2 2024 | $11.0M | -282.8% | $-40.3M | $-46.7M | $-1.71 | — |
| Q1 2024 | $7.2M | -416.0% | $-42.2M | $-43.9M | $-1.64 | — |
| Q4 2023 | $9.0M | -272.3% | $-42.1M | $-42.2M | $-1.57 | — |
| FY 2023 | $17.2M | -671.0% | $-164.4M | $-163.6M | $-6.08 | — |